Inventor · disambiguated record
Nadine Tuaillon
Also filed as: TUAILLON NADINE
18 granted patents·8 pending applications·600 citations·filing 2003–2021
96Inventor score
Top patents by PatentIndex Score
26 records- 0198US8946387B2FcγRIIB specific antibodies and methods of use thereofKOENIG SCOTT·Filed 2008·Granted Feb 3, 2015·82 cites·25 claims
- 0298US8193318B2FcγRIIB specific antibodies and methods of use thereofKOENIG SCOTT·Filed 2008·Granted Jun 5, 2012·77 cites·6 claims
- 0397US8217147B2Identification and engineering of antibodies with variant Fc regions and methods of using sameSTAVENHAGEN JEFFREY·Filed 2006·Granted Jul 10, 2012·93 cites·31 claims
- 0496US10131713B2HER2/neu-specific antibodies and methods of using sameMACROGENICS INC·Filed 2016·Granted Nov 20, 2018·10 cites·20 claims
- 0596US8802093B2HER2/neu-specific antibodies and methods of using sameJOHNSON LESLIE S·Filed 2009·Granted Aug 12, 2014·33 cites·15 claims
- 0696US8187593B2FcγRIIB specific antibodies and methods of use thereofKOENIG SCOTT·Filed 2008·Granted May 29, 2012·63 cites·15 claims
- 0796US7351803B2CD16A binding proteins and use for the treatment of immune disordersMACROGENICS INC·Filed 2003·Granted Apr 1, 2008·78 cites·18 claims
- 0895US9469692B2HER2/neu-specific antibodies and methods of using sameMACROGENICS INC·Filed 2016·Granted Oct 18, 2016·8 cites·14 claims
- 0994US9243069B2HER2/neu-specific antibodies and methods of using the sameMACROGENICS INC·Filed 2014·Granted Jan 26, 2016·13 cites·9 claims
- 1094US7700100B2FcγRIIB fusion proteins and compositions thereofMACROGENICS INC·Filed 2004·Granted Apr 20, 2010·54 cites·4 claims
- 1194US7618628B2CD16A binding proteins and use for the treatment of immune disordersMACROGENICS INC·Filed 2007·Granted Nov 17, 2009·22 cites·23 claims
- 1292US7838635B2CD16A binding proteins and use for the treatment of immune disordersMACROGENICS INC·Filed 2007·Granted Nov 23, 2010·17 cites·19 claims
- 1391US11028183B2HER2/neu-specific antibodies and methods of using sameMACROGENICS INC·Filed 2018·Granted Jun 8, 2021·3 cites·38 claims
- 1491US8968730B2FcγRIIB specific antibodies and methods of use thereofKOENIG SCOTT·Filed 2008·Granted Mar 3, 2015·15 cites·16 claims
- 1590US8697071B2Identification and engineering of antibodies with variant Fc regions and methods of using sameSTAVENHAGEN JEFFREY·Filed 2012·Granted Apr 15, 2014·15 cites·18 claims
- 1687US8778339B2Combination of FcγRIIB-specific antibodies and CD20-specific antibodies and methods of use thereofTUAILLON NADINE·Filed 2008·Granted Jul 15, 2014·14 cites·14 claims
- 1780US9737599B2Combination of FcγRIIB-specific antibodies and CD20-specific antibodies and methods of use thereofMACROGENICS INC·Filed 2014·Granted Aug 22, 2017·3 cites·16 claims
- 1878US12024569B2HER2/neu-specific antibodies and methods of using sameMACROGENICS INC·Filed 2021·Granted Jul 2, 2024·0 cites·21 claims
- 1954US2018092978A1Combination of FcgammaRIIB-Specific Antibodies and CD20-Specific Antibodies and Methods of Use ThereofMACROGENICS INC·Filed 2017·Application pending·0 cites
- 2053US2011152504A1CD16A Binding Proteins and Use for the Treatment of Immune DisordersMACROGENICS INC·Filed 2010·Application pending·0 cites
- 2149US2008112961A1Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using SameMACROGENICS INC·Filed 2007·Application pending·0 cites
- 2244US2006177439A1FcgammaRIIB-specific antibodies and methods of use thereofKOENIG SCOTT·Filed 2005·Application pending·0 cites
- 2344US2010196372A1FcgammaRIIB Fusion Proteins and Compositions ThereofMACROGENICS INC·Filed 2010·Application pending·0 cites
- 2442US2005260213A1Fcgamma-RIIB-specific antibodies and methods of use thereofKOENIG SCOTT·Filed 2005·Application pending·0 cites
- 2539US2007036786A1Method of treating autoimmune disease using humanized anti-CD16A antibodiesTUAILLON NADINE·Filed 2006·Application pending·0 cites
- 2636US2012034221A1T-Cell Receptor Antibodies And Methods of Use ThereofBONVINI EZIO·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →